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Sialic acid-binding immunoglobulin-like lectins (Siglecs) are expressed in various immune 
cells and most of them carry signaling functions. High-affinity synthetic sialoside ligands 
have been developed for various Siglecs. Therapeutic potentials of the nanoparticles and 
compounds that contain multiple numbers of these sialosides and other reagents such as 
toxins and antigens have been demonstrated. However, whether immune responses can 
be regulated by monomeric sialoside ligands has not yet been known. CD22 (also known 
as Siglec-2) is an inhibitory molecule preferentially expressed in B lymphocytes (B cells) 
and is constitutively bound and functionally regulated by α2,6 sialic acids expressed 
on the same cell (cis-ligands). Here, we developed synthetic sialosides GSC718 and 
GSC839 that bind to CD22 with high affinity (IC50 ~100 nM), and inhibit ligand binding 
of CD22. When B  cells are activated by B  cell antigen receptor (BCR) ligation, both 
GSC718 and GSC839 downregulate proliferation of B cells, and this regulation requires 
both CD22 and α2,6 sialic acids. This result suggests that these sialosides regulate BCR 
ligation-induced B cell activation by reversing endogenous ligand-mediated regulation of 
CD22. By contrast, GSC718 and GSC839 augment B cell proliferation induced by TLR 
ligands or CD40 ligation, and this augmentation requires CD22 but not α2,6 sialic acids. 
Thus, these sialosides appear to enhance B cell activation by directly suppressing the 
inhibitory function of CD22 independently of endogenous ligand-mediated regulation. 
Moreover, GSC839 augments B cell proliferation that depends on both BCR ligation and 
CD40 ligation as is the case for in vivo B cell responses to antigens, and enhanced anti-
body production to the extent comparable to CpG oligonuleotides or a small amount of 
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inTrODUcTiOn
Sialic acid-binding immunoglobulin-like lectins (Siglecs) are type 
I membrane proteins expressed in various cell types, especially 
those of immune cells (1). Most of the Siglecs carry signaling 
function, and each member of the Siglec family is expressed in 
specific cell types. Therefore, Siglecs are good targets for immune 
regulation. Although most of the Siglecs bind to sialic acids at 
their extracellular region, each member shows a distinct specific-
ity for the type and linkage of sialic acid (1). In earlier studies, 
Kelm et al. generated various sialosides in which the C2, C5, and 
C9 positions of sialic acid are modified (2), and demonstrated 
that the sialoside α-9-N-(biphenyl-4-carbonyl)-amino-9-deoxy-
Neu5Ac (BPC-Neu5Ac) in which the C9 position was modified 
by a biphenyl markedly improved affinity to human CD22 (4 µM) 
(3). Introduction of galactose at the C2 position was shown to 
further improve affinity to human and mouse CD22 (4, 5). 
Later, we demonstrated that modification of the C9-modified 
sialoside 9-(4′-hydroxy-4-biphenyl)acetamido-9-deoxy-Neu5Gc 
(hydroxy-BPAc-Neu5Gc) at C2 position by hydrophobic groups 
such as benzyl and biphenyl groups augmented affinity to human 
CD22 by 12-fold (70 nM) and mouse CD22 by 38-fold (100 nM) 
(6). This finding suggested that introduction of multiple hydro-
phobic groups in different positions of the sialic acid backbone 
enhances affinity to CD22. Further modifications in multiple 
positions generated sialosides with much higher affinity to 
CD22 (2 nM) (7–10). Efficient synthesis of modified sialosides 
and selection resulted in development of high-affinity synthetic 
ligands of other Siglecs, such as Siglec-1 (11), MAG (12), and 
Siglec-7 (13, 14). Multimers of high-affinity sialoside ligands and 
nanoparticles carrying these sialosides were developed to target 
various molecules such as toxins and antigens to Siglecs. Various 
therapeutic potentials of these multimers and nanoparticles 
have been demonstrated (15, 16). Targeting of toxins to Siglecs 
kills lymphoma cells and leukemia cells (17, 18), suggesting 
therapeutic potential for treatment of the diseases such as leu-
kemia and lymphomas. Targeting lipid antigens to Siglec-1 on 
antigen-presenting cells enhances activation of NKT cells (19). 
Moreover, targeting of antigens to CD22 or Siglec-G expressed 
on B cells co-ligates these Siglecs and the B cell antigen receptor 
(BCR) specific to the antigens, resulting in deletion of the specific 
B  cells and tolerance to the antigens (20–23). The liposomes 
displaying Siglec ligands and antigens are called Siglec-engaging 
tolerance-inducing liposomes (STALs), and appear to be useful in 
prevention of the production of hazardous antibodies. However, 
whether immune responses can be regulated by monomeric 
sialoside ligands has not yet been known.
CD22 (also known as Siglec-2), a member of Siglec family, 
specifically recognizes α2,6 sialic acid, and is preferentially 
expressed in B lymphocytes (B cells) (24, 25). CD22 contains 
immunoreceptor tyrosine-based inhibition motifs (ITIMs) 
in the cytoplasmic region and negatively regulates signaling 
through BCR by recruiting SH2 domain-containing phos-
phatases at the phosphorylated ITIMs. CD22 expressed on 
B cells are mostly bound by α2,6 sialic acids expressed on the 
same cell (cis-ligand) (26), but can interact with exogenous α2,6 
sialic acids (trans-ligand). Interaction with trans-ligands on 
antigen-expressing cells enhances CD22-mediated signal inhi-
bition by co-ligating BCR and CD22 (27, 28). Interaction with 
endogenous ligands, most likely cis-ligands, is also suggested 
to regulate the signaling function of CD22. Early studies with 
B cell lines suggested that the ligand augments signal inhibition 
mediated by CD22 (3, 29). However, B cells that lack expression 
of α2,6 sialic acid due to targeted mutation of ST6GalI, a sialyl 
transferase required for synthesis of α2,6 sialic acid, showed 
reduced BCR signaling due to augmented CD22-mediated 
signal inhibition (30, 31), suggesting that the endogenous 
ligand down-modulates the signal inhibition activity of CD22. 
This conclusion was further supported by the finding that 
BCR signaling is reduced in B cells expressing CD22 that lacks 
ligand-binding capacity (32, 33).
Previously, we developed the C2/C9-modified synthetic 
sialoside GSC718 [compound 8 in Ref. (34)] that binds to both 
human and mouse recombinant CD22 with a 10,000 times higher 
affinity (100 nM) than the natural ligand α2,6 sialic acid. GSC718 
binds to CD22 on the cell surface as well because GSC718 inhib-
its proximity labeling of CD22 ligands using B  cells (35). To 
address whether a monomeric synthetic high-affinity sialoside 
ligand of CD22 can regulate immune responses, we synthesized 
fluorine-substituted form of GSC718 (GSC839) because fluorine 
affects various aspects of compounds including metabolism and 
binding affinity (36), and examined the effect of GSC718 and 
GSC839 on immune responses in  vitro and that of GSC839 
in vivo. These synthetic sialosides inhibited BCR ligation-induced 
B  cell activation by reversing ligand-mediated regulation of 
CD22. By contrast, both GSC718 and GSC839 enhanced B cell 
activation induced by TLR ligands and antibody production by 
ligand-independent mechanism. Thus, CD22-binding synthetic 
sialosides regulate CD22 either positively or negatively, and by 
ligand-dependent and independent mechanisms depending on 
the stimuli, thereby regulating B  cell activation and antibody 
responses in  vivo. Interestingly, homology modeling of CD22 
complexed with GSC839 suggests interactions between aromatic 
moieties of GSC839 with aromatic amino acid residues in CD22 
account for high-affinity binding of GSC839 to CD22 in the 
absence of druggable pockets. Thus, our results suggest how to 
design chemical compounds that regulate members of the Siglec 
family.
alum. Although these known adjuvants induce production of the inflammatory cytokines 
or accumulation of inflammatory cells, CD22-binding sialosides do not. Thus, synthetic 
sialosides that bind to CD22 with high-affinity modulate B cell activation through endog-
enous ligand-dependent and independent pathways, and carry an adjuvant activity 
without inducing inflammation.
Keywords: cD22, glycan ligands, synthetic sialoside, adjuvant, B cell
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MaTerials anD MeThODs
Mice
C57BL/6 mice were purchased from Sankyo Labo Service 
Corporation, Inc. CD22−/− (37) and ST6GalI−/− (38) mice on 
a C57BL/6 background were described previously. Mice were 
used at 8–10 weeks old unless otherwise specified. All mice used 
in this study were bred and maintained in a specific pathogen-
free animal facility of Tokyo Medical and Dental University. 
All procedures followed the guidelines of Tokyo Medical and 
Dental University for animal research and were approved by 
Institutional Animal Care and Use Committee, Tokyo Medical 
and Dental University.
synthetic sialosides
Synthetic sialosides GSC718 were synthesized as previously 
described (6, 34). GSC839 was synthesized via 11 steps starting 
from the glycosylation of 4-fluorobenzyl alcohol with 5N-TFAc, 
9-N3-modified sialyl thioglycoside donor. The glycosylation 
afforded a mixture of α- and β-sialosides that were separated via 
1,5-lactamization. Acetylation of the α-4-fluorobenzyl sialoside 
followed by selective removal of N-acetyl group with hydrazine 
acetate gave the lactamized compound as a single product in 
good yields. Subsequent introduction of the Boc group at the C5 
position afforded the fully protected sialoside derivative. Lactam 
opening by treatment of NaOMe in anhydrous MeOH was 
achieved successfully to give the desired triol product in the 2C5 
conformation in excellent yield. Next, the reduction of the azide 
functionality with triphenylphosphine in THF-H2O followed by 
the condensation with the carboxylic acid derivative produced 
the amide product in good yields over two steps. Finally, the 
conversion of the Boc carbamate into the acetoxyglycolyl amide 
at C5 position and subsequent global deprotection furnished the 
target GSC839 in good yields. Synthesis of GSC839 is described in 
more detail in Presentation S1 in Supplementary Material.
cell isolation and culture
Mouse spleen B  cells were prepared as described previously 
(39). Peritoneal exudate cells were collected by intraperitoneal 
injection of ice-cold RPMI-1640 medium. In some experiments, 
peritoneal exudate cells were incubated in 24-well cell culture 
plate for 1 h. After discarding non-adherent cells, adherent cells 
were collected by treatment with Trypsin/EDTA (Nakalai). For 
preparation of total spleen cells, mouse spleen was incubated 
in Hank’s balanced salt solution (Wako) containing 0.1% colla-
genase (Sigma) at 37°C for 20 min, and minced. Cells were then 
collected. Bone marrow cells were obtained from mouse femur 
and tibia by flushing with RPMI-1640 medium. For preparation 
of bone marrow-derived DCs (BMDCs), 1 × 106 bone marrow 
cells were cultured in 1 ml RPMI-1640 medium supplemented 
with 10% FCS (Nichirei Biosciences) 50 µM 2-mercaptoethanol 
(Sigma), and 1% penicillin/streptomycin (Nakalai) (complete 
RPMI-1640 medium) containing 200  ng/ml human Flt3L 
(Peprotech) or 10  ng/ml human GM-CSF (Peprotech) for 6–9 
and 6  days, respectively. Total spleen cells and BMDCs were 
cultured with CpG oligo or LPS in the presence or absence of 
80 µM GSC718 or GSC839 for 24 h.
cell Proliferation assay
Cells were labeled with 10 µM carboxyfluorescein diacetate succin-
imidyl ester (CFSE) (molecular probes) for 10 min. CFSE-labeled 
or unlabeled cells (2 × 105) were cultured in 200 µl complete RPMI-
1640 medium in 96-well plate with CpG oligonucleotides (CpG 
oligo) (ODN1668) (Hokkaido System Science), F(ab′)2 fragments 
of goat anti-mouse IgM antibody (Jackson ImmunoResearch), 
LPS (Sigma, E. coli. O111:B4), or anti-CD40 antibody (FGK45) 
(40) (a kind gift of Dr. Rolink), in the presence or absence of 50 µM 
GSC718 or GSC839 for 72 h. Percentages of cells with reduced 
CFSE fluorescence were measured as divided cells.
assay for B cell Proliferation That 
Depends on Both Bcr and cD40 ligation
Mouse spleen B cells were labeled with CFSE. Cells were cultured 
in complete RPMI medium with or without 1, 3, or 10 µg/ml anti-
CD40 antibody (FGK45) and 10 μg/ml F(ab′)2 fragments of goat 
anti-mouse IgM antibody (Jackson ImmunoResearch). After 5 h, 
cells were washed twice and then cultured with or without 1, 3, 
and 10 µg/ml anti-CD40 antibody (FGK45). Cells were cultured 
in total 72 h and analyzed by flow cytometry.
Flow cytometry
Cells were incubated with anti-FcγRII/III antibody 2.4G2 for 10 min 
to block FcγRII/III-mediated binding, and stained for 30 min with 
the following antibodies: FITC-conjugated anti-mouse B7.2 (GL1, 
BD Pharmingen), biotin-conjugated MHC class II I-A/I-E (2G9, 
BD Pharmingen), PE-labeled streptavidin (BioLegend), Alexa647-
conjugated anti-mouse F4/80 (BM8, BioLegend), eFluor450-
conjugated anti-mouse CD11c (N418, eBioscience), biotinylated 
anti-mouse CD22 (F239), biotinylated anti-mouse Gr-1 (RB6-8C5), 
Pacific blue-conjugated anti-mouse CD45R (RA3-6B2), Alexa647- 
or FITC-conjugated  anti-mouse CD3 (145-2C11, BioLegend), 
FITC-conjugated anti-mouse CD11b (M1/70, BioLegend), and 
FITC-conjugated anti-mouse CD19 (eBio1D3, eBioscience). Cells 
were washed twice with PBS containing 2% FCS (FACS buffer) and 
then suspended in FACS buffer. All these procedures were done 
on ice. In peritoneal cells, total macrophages (CD11b+i F4/80+i), 
large peritoneal macrophages (LPM) (CD11bhi F4/80hi), small 
peritoneal macrophages (SPM) (CD11b+ F4/80lo), and neutrophils 
(CD11b+ F4/80−, Gr-1+) were defined. CD11b+Gr1+ bone marrow 
cells were gated as bone marrow granulocytes. Spleen dendritic 
cells (DCs) were defined as CD3−CD19−NK1.1−CD11c+. Spleen 
T and B cells were defined as CD3+B220− and CD3−B220+ cells in 
lymphocyte gate (FSClo, SSClo). Cells were analyzed using a CyAn 
(Beckman Courter) or FACSVerse™ (BD).
competition elisa for Binding 
of sialosides to cD22
Recombinant proteins composed of the amino-terminal domains 
(domains 1–3) of mouse or human CD22 and the Fc region of 
human IgG1 (CD22-Fc) were described previously (41). Microtiter 
plates (96 well) were coated with 20 µg/ml α1-acid glycoprotein 
(Sigma). Alternatively, plates were coated with 50 µg/ml strepta-
vidin followed by incubation with 4 µg/ml biotinylated synthetic 
CD22 ligand (42). Plates coated with α1-acid glycoprotein and 
FigUre 1 | High-affinity binding of GSC718 and GSC839 to CD22. (a) Structure of GSC718 and GSC839. (B,c) Competition ELISA for measuring affinity of 
GSC718 and GSC839 to ligand. Indicated concentrations of GSC718 (closed circles) or GSC839 (open circles) and mouse (B) or human CD22-Fc (c) protein 
were incubated in wells coated with synthetic CD22 ligand (B) or α1-acid glycoprotein (c), and binding of CD22-Fc to these ligands was detected by ELISA. 
Percent binding inhibition by the sialosides, and the concentration of sialosides that achieves 50% binding inhibition (IC50) were calculated.
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synthetic CD22 ligand were then blocked with PBS containing 
1% bovine serum albumin, followed by incubation with human 
or mouse CD22-Fc and compounds for 2 h, respectively. CD22-Fc 
bound to the plates was detected using alkaline phosphatase 
(AP)-conjugated goat anti-human IgG (Southern Biotechnology) 
and AP substrate solution (Sigma). The optical density at 405 nm 
was measured by a microplate reader (Molecular Devices). The 
concentrations of the compounds that reduce the binding of 
CD22-Fc to the biotinylated CD22 ligand and α1-acid glyco-
protein by 50% (IC50) were determined.
Measurement of TnFα
TNFα and IL-6 were measured by TNFα ELISA kit and IL-6 
ELISA kit (BioLegend), respectively, according to the manufac-
ture’s protocol.
immunization
Mice were intraperitoneally or subcutaneously immunized with 2.5 
or 10 µg ovalbumin (OVA) (Sigma) in PBS with or without 100 µg 
GSC839, 20, 50, or 100 µg CpG oligo or 0.15, 0.5, or 1.5 µl Alhydrogel 
(In vivoGen) containing 3, 10, or 30 µg alum, respectively. Blood 
samples were collected after 24  h for measurement of cytokine 
production and after 3  weeks for measurement of OVA-specific 
antibody production. In some mice, 2.5 µg OVA was injected sub-
cutaneously without any adjuvants at 9 weeks after primary immu-
nization to induce memory responses (43). Serum samples were 
collected 1 week later for measurement of OVA-specific antibodies.
Measurement of anti-OVa igg
Microtiter plates (96 well) were coated with 100 µg/ml OVA at 
4°C overnight. Plates were washed with PBS twice, and blocked 
with PBS containing 1% bovine serum albumin for 2 h at room 
temperature. After discarding the blocking buffer, serially diluted 
serum samples were added to the wells, and incubated for 2 h 
at room temperature. After washing with PBS containing 0.05% 
tween 20 (PBS-T) five times, wells were incubated with alkaline 
phosphatase (AP)-conjugated goat anti-mouse IgG, IgG1, IgG2b 
(Southern Biotechnology) for 1 h at room temperature. Alterna-
tively, wells were incubated with biotin-conjugated goat anti-
mouse IgG2c (Abcam) for 1  h, followed by incubation with 
AP-conjugated streptavidin for 30  min. After washing with 
PBS-T five times, wells were incubated with AP substrate solution 
(Sigma). After incubation at room temperature for approximately 
20 min, optical density at 405 nm was measured by microplate 
reader (Molecular Devices).
statistical analysis
Data of in vitro experiments were analyzed by unpaired two-tailed 
t-test. Data of in  vivo immunization were analyzed by Mann–
Whitney test, Wilcoxon signed-rank test, or Kruskal–Wallis test. All 
the analysis was done using GraphPad PRISM software (GraphPad) 
or EZR. P-values <0.05 were regarded as statistically significant.
homology Modeling
A homology model of CD22 were generated by SWISS-MODEL 
Workspace (44) using the coordinates of the ligand-binding 
domain of human CD22 (45) (PDB ID 5VKM, residues 20–138) 
as a template structure. The figures of the sequence alignment and 
molecular models are prepared using ESPript (46) and PyMOL 
(The PyMOL Molecular Graphics System, Schrödinger, LLC.), 
respectively.
resUlTs
cD22-Binding sialosides gsc718 and 
gsc839 enhance B cell Proliferation 
induced by Tlr ligands or cD40 ligation, 
but Downregulate Bcr ligation-induced 
B cell Proliferation
We synthesized the novel sialoside GSC839 by introducing fluo-
rine atom into GSC718 at the C-4 position of the benzyl group 
(Figure 1A). When we measured the binding affinity of GSC839 
to CD22 by a competition ELISA using the fusion protein 
FigUre 2 | GSC718 and GSC839 downregulate B cell proliferation induced by BCR ligation in vitro. Spleen B cells obtained from wild type (WT) (a–D), CD22−/− 
(c,D), and ST6GalI−/− (a,B) C57BL/6 mice were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cultured for 72 h in the presence of 
indicated concentrations of anti-IgM with or without 50 µM GSC718 (a,c) or GSC839 (B,D). Cells were analyzed by FCM and percentages of proliferated cells 
are indicated (left panels). Data are representative of at least three experiments. Mean ± SD (n = 3) is shown (right panels). Data were analyzed by unpaired t-test. 
*P < 0.05, NS, not significant.
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containing the ligand-binding domain of CD22 and the Fc por-
tion of human IgG (CD22-Fc), GSC839 bound to both human 
and mouse CD22 with comparable affinities (IC50 ~100 nM) and 
these affinities are similar to those of GSC718 (Figures 1B,C).
We addressed whether the CD22-binding sialosides modulate 
B  cell proliferation. We first addressed the effect of the CD22-
binding sialosides on BCR ligation-induced B cell proliferation. 
Treatment with GSC718 or GSC839 modestly but significantly 
reduced proliferation of wild-type (WT) B cells stimulated with 
anti-IgM (Figures  2A–D). Although ST6GalI−/− B  cells were 
previously shown to be activated less efficiently by various stimuli 
(31, 38), anti-IgM induced proliferation of ST6GalI−/− B cells as 
efficiently as WT B cells probably because of a different assay to 
address cell proliferation from the previous studies. Treatment 
with GSC718 or GSC839 did not alter proliferation of anti- 
IgM-stimulated ST6GalI−/− B  cells (Figures  2A,B) or CD22−/− 
B  cells (Figures  2C,D), suggesting that the effect of GSC718 
and GSC839 to reduce BCR ligation-induced B cell proliferation 
requires both CD22 and CD22 ligands. Thus, CD22-binding sia-
losides down-modulate BCR ligation-induced B cell proliferation 
by reversing ligand-mediated regulation on CD22.
Because CD22−/− B cells show an augmented response to TLR 
ligands and CD40 ligation (33, 47–49), we examined whether 
GSC718 and GSC839 modulate activation of B cells treated with 
agonistic anti-CD40 antibody or the TLR ligands CpG oligo and 
LPS. Upon stimulation with anti-CD40 antibody or CpG oligo, 
CD22−/− B  cells showed augmented proliferation compared to 
WT B cells in agreement with the previous findings (33, 47, 48) 
(Figures 3A–D). Treatment with GSC718 or GSC839 enhanced 
proliferation of WT B cells stimulated with anti-CD40 antibody 
or low-dose CpG oligo probably by inhibiting CD22-mediated 
signal inhibition. By contrast, both GSC718 and GSC839 failed 
to augment proliferation of CD22−/− B cells, suggesting that these 
sialosides require CD22 for enhancing B  cell activation. Thus, 
GSC718 and GSC839 enhance proliferation of B cells stimulated 
with CD40 ligation or CpG oligo by reversing CD22-mediated 
inhibition of B cell activation.
To address the role of endogenous CD22 ligands in the B cell 
responses to CD40 ligation and TLR ligands, we examined the 
responses of ST6GalI−/− B cells. When stimulated with anti-CD40 
antibody or low-dose TLR ligands, such as LPS and CpG oligo, 
proliferation of ST6GalI−/− B cells was comparable to that of WT 
B cells (Figures 3E–H).This result indicates that CD22 ligands 
do not regulate B cell proliferation induced by CD40 ligation or 
TLR ligands. Treatment with GSC718 augmented proliferation 
of ST6GalI−/− B  cells induced by TLR ligands (Figures  3E,F) 
as strongly as that of WT B cells, indicating that GSC718 aug-
ments activation of TLR ligands-stimulated B cells by a ligand- 
independent pathway. GSC718 also augmented proliferation of 
anti-CD40-stimulated B cells. In the presence of anti-CD40 and 
GSC718, the proliferation of ST6GalI−/− B cells was comparable to 
but slightly less than that of WT B cells. Essentially the same results 
FigUre 3 | GSC718 and GSC839 augment B cell proliferation induced by anti-CD40 and TLR ligands in vitro. Spleen B cells obtained from wild type (WT) 
(a–h),CD22−/− (a–D), and ST6GalI−/− (e–h) C57BL/6 mice were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) and cultured for 72 h in the 
presence of indicated concentrations of anti-CD40 (a–h), CpG oligo (a–h), or LPS (e–h) with or without 50 µM GSC718 (a,B,e,F) or GSC839 (c,D,g,h). Cells 
were analyzed by FCM and percentages of proliferated cells are indicated (a,c,e,g). Data are representative of at least three experiments. Mean ± SD (n = 3) is 
shown (B,D,F,h). Data were analyzed by unpaired t-test. **P < 0.01, ***P < 0.001, NS, not significant.
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FigUre 4 | GSC839 augments proliferation of B cells stimulated with anti-IgM together with anti-CD40. Spleen B cells obtained from wild-type C57BL/6 mice were 
stimulated with 10 µg/ml anti-IgM for either 72 h or initial 5 h together with indicated concentrations of anti-CD40 for 72 h. Schematic diagram illustrating time 
course of B cell stimulation (a). Cells were analyzed by FCM and percentages of proliferated cells are indicated (B). Data are representative of three experiments. 
Mean ± SD (n = 3) is shown (c). Data were analyzed by unpaired t-test. **P < 0.01, ***P < 0.001.
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were obtained with treatment with GSC839 (Figures  3G,H). 
Thus, CD22-binding sialosides appear to augment B cell prolif-
eration by reversing inhibitory function of CD22 independently 
of CD22 ligands.
Taken together, both GSC718 and GSC839 augment B  cell 
proliferation induced by TLR ligands or anti-CD40 in a man-
ner independent on CD22 ligands, but down-modulates BCR 
ligation-induced B cell proliferation by reversing ligand-mediated 
regulation on CD22.
gsc839 augments B cell Proliferation 
induced by combination of cD40 
ligation and Bcr ligation
When B cells respond to antigens, antigen-induced BCR signal-
ing alone does not induce proliferation of B cells (50), and pro-
liferation of antigen-stimulated B  cells requires co-stimulatory 
signaling through CD40 (51). Continuous BCR ligation by 
anti-IgM antibody for 72 h induces B cell proliferation. However, 
treatment with anti-IgM antibody for the first 5 h of the culture 
does not induce B cell proliferation by itself, but induces B cell 
proliferation in the presence of a low dose anti-CD40 antibody 
(1 or 3 µg/ml), whereas the low dose anti-CD40 alone induces 
only marginal proliferation (Figures 4A–C). Thus, in the culture 
condition where B  cells are stimulated with anti-IgM for 5  h 
together with a low-dose anti-CD40 for 72 h, B cell proliferation 
requires both BCR ligation and CD40 signaling as is the case for 
in vivo B cell responses to antigens. Activity of GSC839 in binding 
to CD22 and inducing B  cell proliferation is similar to that of 
GSC718. Thus, we chose GSC839 simply due to availability for 
in vivo study and added GSC839 to this culture. B cell prolifera-
tion induced by treatment with anti-IgM antibody for the first 5 h 
together with the low-dose anti-CD40 was further enhanced by 
GSC839, suggesting that GSC839 enhances B cell activation that 
depends on both BCR ligation and CD40 signaling.
gsc718 and gsc839 Do not activate 
innate immune cells
To address whether CD22-binding sialosides activate other 
immune cells than B cells, we examined expression of CD22 in 
various immune cell types. Splenic DCs expressed CD22 at a level 
lower than B cells do in agreement with the previous finding (52), 
whereas CD22 was not expressed in the other innate immune 
cells such as macrophages and granulocytes (Figure  5A). To 
further address CD22 expression on DCs, we generated DCs by 
culturing mouse bone marrow cells with Flt3L or GM-CSF. CD22 
expression was detected in both Flt3L- and GM-CSF-induced 
DCs (Figure 5B).
To address whether GSC718 and GSC839 activate DCs, we 
stimulated GM-CSF-induced BM DCs with GSC718 in the pres-
ence or absence of small amounts of TLR ligands, and examined 
expression of activation markers such as CD80, CD86, CD40, 
and MHCII because GM-CSF-induced BM DCs showed higher 
CD22 expression than spleen DCs. Although treatment with TLR 
ligands alone enhanced expression of CD80, CD86, and CD40, 
FigUre 5 | Continued
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almost no upregulation of these markers were induced by 
GSC718 and GSC839 regardless of presence or absence of TLR 
ligands (Figures  5C,D). MHCII was not augmented by the 
treatment with TLR ligands at the tested concentrations. Thus, 
CD22-binding sialosides fail to activate DCs probably because 
of low CD22 expression.
FigUre 5 | GSC718 does not enhance TNFα production. (a) CD22 expression in various cells. PEC, BM cells, and splenocytes were obtained from wild type (solid 
lines) or CD22−/− C57BL/6 mice (dotted lines). F4/80+CD11c+ peritoneal macrophages, Gr1+ BM granulocytes, CD3−CD19−NK1.1−CD11c+ spleen dendritic cells 
(DCs), CD3−B220+ spleen B cells, CD3+B220− spleen T cells were analyzed for CD22 expression by FCM. MFIs are indicated. (B–D) GSC718 does not activate 
DCs. DCs were generated by culturing bone marrow cells from C57BL/6 mice with Flt3L or GM-CSF and were analyzed for CD22 and CD11c by FCM (B). Gating 
strategy of CD11c+ cells and expression level of CD22 in comparison to FMO control (dotted line) in CD11c+ cells are shown. MFIs are indicated. Cells were 
stimulated with 10 nM CpG oligo or 0.02 µg/ml LPS with (red) or without (blue) 80 µM GSC718 (c) or GSC839 (D), and expression of CD86 (c), CD80, MHCII, 
and CD40 (c,D) was analyzed by FCM. MFI is indicated. Representative data of three experiments. (e–h) TNFα production in vitro. Whole spleen cells were 
obtained from C57BL/6 mouse and cultured for 24 h with indicated concentrations of CpG or LPS in the presence (gray columns) or absence (white columns) 
of 50 µM GSC718 (e) or GSC839 (F), or indicated concentrations of GSC718 (g) or GSC839 (h). n = 3. Error bars show mean ± SD.
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Next, we addressed whether these CD22-binding sialosides 
induce inflammatory responses. When we cultured total mouse 
spleen cells with GSC718 or GSC839, the level of TNFα was 
not increased in culture supernatant whereas TLR ligands such 
as CpG oligo and LPS induced TNFα production in these cells 
(Figures 5E–H). As GSC718 and GSC839 enhance activation of 
B cells induced by TLR ligands, we examined whether these sia-
losides enhance production of inflammatory cytokines induced 
by TLR ligands. However, neither GSC718 nor GSC839 enhanced 
TNFα production from total spleen cells stimulated with CpG 
oligo or LPS. Thus, CD22-binding sialosides do not induce 
inflammatory response by itself or enhance the inflammatory 
response to TLR ligands.
gsc839 carries an adjuvant activity
Because GSC839 enhances in vitro B cell activation that depends 
on both BCR and CD40 signaling, we hypothesized that GSC839 
enhances in vivo B cell responses to antigens as well. To address 
this possibility, we subcutaneously immunized mice with OVA 
together with GSC839 or known adjuvants such as CpG oligo and 
alum. Mice immunized with OVA together with GSC839 showed 
significantly higher antibody titers than those immunized with 
OVA alone (Figure 6A). The total anti-OVA IgG titers induced 
by GSC839 were comparable to those induced by CpG oligo 
and a small amount of alum, but lower than those induced by 
larger amounts of alum (Figure 6B). GSC-839 failed to enhance 
antibody production when mice were immunized with a higher 
amount of OVA (Figure 6C).
As IgG2b and IgG2c are more pro-inflammatory than IgG1, 
we addressed IgG subtypes of specific antibodies induced by 
GSC839. The titers of anti-OVA IgG1 induced by OVA together 
with GSC839 were significantly higher than those induced by 
OVA alone (Figure 6A), and comparable to those induced by OVA 
together with CpG oligo or a small amount of alum (Figure 5B). 
By contrast, GSC839 did not augment production of IgG2b or 
IgG2c (Figure 6A), and the titers of anti-OVA IgG2b and IgG2c 
induced by GSC839 were much lower than those induced by CpG 
oligo (Figure 6B).
We next addressed whether GSC839 augments immunological 
memory. We immunized mice with OVA together with GSC839, 
CpG oligo, or alum, and, after 9 weeks, boosted the mice with 
OVA alone. The antibody titer was significantly increased after 
boost compared to that before the boost in mice primed with 
OVA together with GSC839 as well as mice primed with OVA 
together with CpG oligo or a small amount of alum (Figure 6D). 
This result indicates that GSC839 augments immunological 
memory as well as primary antibody responses.
To address whether GSC839 augments antibody production 
by regulating CD22, we immunized mice with OVA together 
with GSC839 either intraperitoneally or subcutaneously. GSC839 
augmented antibody production in WT but not CD22−/− mice 
regardless of the route of immunization (Figures  6E,F). This 
result clearly indicates that GSC839 augments antibody produc-
tion by regulating CD22.
gsc839 Does not induce inflammation 
in Mice
To address whether GSC839 induces inflammation in  vivo, 
we subcutaneously immunized mice with OVA together with 
GSC839, CpG oligo, or alum, and measured cytokine production 
in sera. Both TNFα and IL-6 were produced by CpG oligo but 
not GSC839 or alum (Figure 7A). Next, we injected GSC839 and 
alum intraperitoneally, and analyzed peritoneal exudate cells. 
In peritoneal cells from mice treated with alum, the percentage 
of LPM (53), which are resident macrophages, was significantly 
reduced whereas the percentages of both SPM, which are blood-
derive inflammatory macrophages, and neutrophils (53), were 
increased, suggesting that alum induces peritoneal inflammation 
(Figures 7B,C). By contrast, treatment with GSC839 did not alter 
the percentage of macrophages or neutrophils, clearly demon-
strating that GSC839 does not induce inflammation in vivo.
homology Model of cD22 Bound 
by gsc839
We generated a homology model of the ligand-binding domain 
of CD22 based on the crystal structure of human CD22 (45). 
Amino acid sequence alignment between mouse and human 
CD22 (Figure 8A) show 53% identity. The overall structure of 
the obtained model of mouse CD22 (Figure 8B) is quite similar 
to that of human CD22 (45). We analyzed presence of potential 
binding pockets by MetaPocket 2.0 server (54). No pockets are 
present around conserved Arg130, which forms a salt bridge with 
the carboxylate group of sialic acid.
Next, we generated the model of CD22 complexed with 
GSC839 (Figure 8B). We used structures of Me-α-9-N-(biphenyl-
4-carbonyl)-amino-9-deoxy-Neu5Ac (BPC-Neu5Ac) and PROP 
(2-benzyl-Neu5NPro) compounds bound to Siglec-1 (55, 56) as 
templates, and generated a model of GSC839 bound to CD22 in 
such a way that the benzyl and the biphenyl groups of GSC 839 
correspond to the benzyl group of PROP and the biphenyl group 
of BPC-Neu5Ac, respectively. It is also taken into account that 
GSC839 contains an additional carbon chain between the C9 
position of sialic acid and the biphenyl group and a hydroxy group 
FigUre 6 | Continued
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at the tip of the biphenyl group compared to BPC-Neu5Ac. The 
homology model of GSC839-bound mouse CD22 reveals favora-
ble interactions between the aromatic moieties of both the benzyl 
and biphenyl groups of GSC839 and Phe68 and Tyr66, respectively 
(Figure 8B). Both residues are able to form π–π interactions and 
contribute to the high affinity of GSC839 to mouse CD22.
DiscUssiOn
Here, we demonstrated that the synthetic sialoside GSC718 and 
GSC839 bind to both human and mouse recombinant CD22 pro-
teins with high affinity (IC50 ~100 nM). These sialosides bind 
to CD22 expressed on the cell surface as well because we recently 
FigUre 6 | GSC839 promotes antibody production in vivo. (a) Augmented antibody production by GSC839. C57BL/6 mice were subcutaneously immunized 
with 2.5 µg ovalbumin (OVA) together with or without 100 µg GSC839. The titers of serum anti-OVA IgG, IgG1, IgG2b, and IgG2c at day 21 were measured by 
ELISA. Data were analyzed by Mann–Whitney test. *P < 0.05, **P < 0.01. (B) Comparison of the effect of GSC839 on antibody production with that of other 
adjuvants. C57BL/6 mice were subcutaneously immunized with 2.5 µg OVA together with the indicated amounts of GSC839, CpG oligo, or alum. The titers 
of serum anti-OVA IgG, IgG1, IgG2b, and IgG2c at day 21 were measured by ELISA. Difference between the antibody titers induced by GSC839 and those 
induced by LPS or CpG oligos was analyzed by Kruskal–Wallis test, and Steel test was applied as post hoc analysis. *P < 0.05. (c) GSC839 fails to augment 
antibody responses to a higher amount of antigen. C57BL/6 mice were subcutaneously immunized with 10 µg OVA together with or without 100 µg GSC839. 
The titers of serum anti-OVA IgG at day 21 were measured by ELISA. Data were analyzed by Mann–Whitney test. NS, not significant. (D) GSC839 augments 
immunological memory. C57BL/6 mice were subcutaneously immunized with 2.5 µg OVA together with indicated amounts of GSC839, CpG oligo, or alum. 
After 9 weeks, mice were intravenously boosted with 2.5 µg OVA. The titers of serum anti-OVA IgG before and 7 days after boost were measured by ELISA. 
Data were analyzed by Wilcoxon signed-rank test. *P < 0.05, **P < 0.01, NS, not significant. (e,F) CD22 is required for the adjuvant effect of GSC839. Wild 
type and CD22−/− C57BL/6 mice at 7–11 weeks old were intraperitoneally (e) or subcutaneously (F) immunized with 2.5 µg OVA with or without 100 µg 
GSC839, and the titers of serum anti-OVA IgG at day 21 were measured by ELISA. Data were analyzed by Mann–Whitney test. *P < 0.05, **P < 0.01, NS, 
not significant.
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demonstrated using proximity labeling that GSC718 inhibits 
association of cell surface CD22 with its glycan cis-ligands (35). 
Both GSC718 and GSC839 modulate in vitro activation of mouse 
B cells and enhance antibody production in mice. These sialosides 
do not regulate activation of CD22−/− B cells or enhance antibody 
production in CD22−/− mice, suggesting that these sialosides spe-
cifically regulate CD22. Treatment with these synthetic sialosides 
down-modulates B  cell proliferation induced by BCR ligation, 
whereas the same treatment does not alter BCR ligation-induced 
proliferation of ST6GalI−/− B cells, suggesting that this effect of the 
sialosides depends on endogenous CD22 ligands. Because CD22 
ligands are suggested to augment BCR signaling by inhibiting 
CD22 function (30–33), GSC718 and GSC839 appear to down-
modulate BCR ligation-induced B cell proliferation by reversing 
ligand-mediated regulation on CD22. By contrast, both GSC718 
and GSC839 augment proliferative responses to TLR ligands 
and CD40 ligation in vitro in WT but not CD22−/− B cells. CD22 
inhibits proliferative responses to TLR ligands and CD40 ligation 
(33, 47–49) as well as BCR ligation-induced signaling (24, 25), 
although it is not yet clear how CD22 regulates signaling through 
CD40 and TLRs. Therefore, GSC718 and GSC839 appear to sup-
press CD22 thereby enhancing B cell responses to TLR ligands 
and CD40 ligation. Because these sialosides enhance proliferative 
responses to TLR ligands in ST6GalI−/− as well as WT B cells, CD22 
ligands are not required for this effect of the sialosides. These 
sialosides also enhance proliferation of anti-CD40-stimulated 
ST6GalI−/− B cells. Proliferation of ST6GalI−/− B cells stimulated 
with anti-CD40 and sialosides are slightly less than that of WT 
B cells. There might be a minor involvement of α2,6 sialic acid 
in CD40-mediated B  cell activation although the mechanism 
is not clear. Thus, GSC718 and GSC839 may directly inhibit 
CD22 by binding to CD22. Taken together GSC718 and GSC839 
downregulate BCR ligation-induced B cell activation by reversing 
ligand-mediated regulation on CD22, but augment B cell activa-
tion by TLR ligands or CD40 ligation through direct inhibition 
of CD22. It is not yet clear how CD22-binding sialosides regulate 
CD22 differentially in the presence or absence of BCR ligation. 
One possible mechanism may be that BCR ligation activates 
CD22 ligands to regulate CD22, thereby overwhelming the direct 
inhibition of CD22 induced by CD22-binding sialosides.
Here, we demonstrated that GSC839 augments proliferation 
of B cells stimulated with transient BCR ligation and continuous 
CD40 ligation. With these stimuli, B cell proliferation depends 
on both BCR and CD40 signaling as is the case for in vivo B cell 
responses to antigens (51). Although B cell proliferation induced 
by continuous BCR ligation is reduced by GSC839, GSC839 
augments B cell proliferation induced by transient BCR ligation 
with or without anti-CD40. GSC839 might differentially regulate 
CD22-mediated signal inhibition either between early and late 
phases of the culture or between BCR signaling and signaling 
induced by other stimuli such as CD40 ligation or mitogenic  factors 
in the culture though mechanisms for the differential  regulation 
is not yet clear. Moreover, we demonstrated that GSC718 and 
GSC839 augment B  cell response to TLR ligands and CD40 
ligation. CD40 signaling is crucial for T  cell-dependent B  cell 
activation (57) and enhances plasma cell differentiation (58, 59). 
TLR signaling in B cells is shown to be important for antibody 
response (60–64). Thus, augmented proliferation induced by the 
combination of BCR ligation and CD40 ligation, and enhanced 
reactivity to CD40 ligation and TLR ligands may account for the 
adjuvant activity of GSC839.
Sialic acid-containing antigens suppress B  cell activation 
and antibody production by interacting with both BCR and 
CD22, thereby enhancing CD22-mediated signal inhibition 
(28, 65). However, CD22 appears to suppress B  cell responses 
to non-sialylated antigens because CD22 down-modulates BCR 
signaling induced by F(ab′)2 fragments of anti-IgM devoid of 
glycosylation(37, 66–68). Thus, reversal of CD22-mediated sig-
nal inhibition augments B cell activation to both sialylated and 
non-sialylated antigens though B  cell response to sialylated 
antigens may be more strongly augmented by CD22 inhibition. 
Here, we demonstrate that GSC839 augments antibody responses 
to OVA, which is not sialylated (69). Because CD22 suppresses 
B  cell response to both sialylated and non-sialylated antigens, 
GSC839 augments antibody responses to OVA by reversing 
CD22-mediated signal inhibition.
Although various compounds have been isolated that enhance 
immune responses, most of them augment immune response by 
activating pattern recognition receptors (PRR) such as TLRs (70). 
PRR ligands activate DCs crucial for T cell activation, but also 
activate inflammatory cells such as macrophages and neutrophils. 
By contrast, both GSC718 and GSC839 bind to CD22 expressed 
in B cells and DCs but not macrophages or neutrophils. GSC718 
does not activate DCs probably because of low CD22 expression 
in these cells. In vivo treatment of GSC839 does not induce 
production of inflammatory cytokines or induce recruitment of 
FigUre 7 | In vivo treatment with GSC839 does not induce inflammation. (a) Production of inflammatory cytokines. C57BL/6 mice were subcutaneously 
immunized with 2.5 µg ovalbumin together with indicated amounts of GSC839, CpG oligo, or alum. The levels of serum TNFα and IL-6 24 h after immunization 
were measured by ELISA. Data were analyzed by Kruskal–Wallis test and Steel analysis was applied as post hoc analysis. *P < 0.05. (B,c) C57BL/6 mice were 
intraperitoneally injected with indicated amounts of alum or GSC839. After 24 h, peritoneal cells were collected and analyzed for CD11b, F4/80, and Gr-1 by FCM. 
(B) Representative data. The percentages of large peritoneal macrophages (LPM) (CD11bhi F4/80hi), small peritoneal macrophages (SPM) (CD11b+ F4/80lo), and 
neutrophils (CD11b+ F4/80−, Gr-1+) are indicated. (c) Combined data from five experiments. Percentages of indicated cells in total peritoneal cells are shown. 
Data were analyzed by Kruskal–Wallis test and Steel analysis was applied as post hoc analysis. *P < 0.05.
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inflammatory cells, whereas CpG and alum induce production 
of inflammatory cytokines and recruitment of inflammatory 
cells, respectively. Thus, CD22-binding sialosides do not induce 
inflammatory responses probably because it specifically activates 
B  cells. Lack of inflammation may lead to preferential IgG1 
production induced by GSC839. Moreover, CD22−/− mice do 
not develop either inflammatory or autoimmune diseases. This 
finding supports the safety of GSC839 because GSC839 appears 
to augment antibody production by suppressing CD22. Here, 
we failed to demonstrate how these sialosides enhance antibody 
production in vivo because the adjuvant effect of these sialosides 
was clear when subcutaneously immunized with a small amount 
(2.5 µg) but not a larger amount (10 µg) of the antigen (OVA). 
Immunization with the small amount of the antigen induces 
FigUre 8 | Homology modeling of CD22 complexed with GSC839. (a) Amino acid sequence alignment of the ligand-binding domain of mouse CD22 and human 
CD22. White characters on a red background are identical residues. Similar residues are highlighted as red characters and framed in blue. Sequence number of 
mouse CD22 are indicated every 10 residues. (B) Homology model of CD22 (surface model, yellow). Model of bound GSC839 is represented as a stick model. 
Aromatic residues that interact with GSC839 are indicated as green stick models.
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antibody production but did not induce measurable changes 
in immune cells. With a larger amount of the antigen, B  cell 
activation may depend more on BCR signaling, which is down-
modulated by CD22-binding sialosides. When immunized with 
a small amount of antigen, GSC839 enhances specific antibody 
production by itself as efficiently as CpG oligo that is now under 
clinical trial as a vaccine adjuvant for human (71). Thus, CD22-
binding sialosides that enhance specific antibody production 
without inducing inflammation may be a good candidate for a 
safe adjuvant for human.
Only a small fraction of the proteins involved in diseases can 
be regulated by small chemical compounds. Druggability was 
addressed initially by homology to the proteins that are regulated 
by chemical compounds, but later by the presence of molecular 
pockets that can accommodate chemical compounds (72, 73). 
Here, we generated a molecular model of mouse CD22 com-
plexed with GSC839, and demonstrated that aromatic moieties 
in GSC839 may form π–π interactions with the aromatic amino 
acid residues Phe68 and Tyr66 in CD22 without involvement of 
a molecular pocket. Previously, Zaccai et al. generated a model of 
human CD22 complexed with BPC-Nue5Ac, and suggested that 
the biphenyl group of BPC-Neu5Ac is sandwiched by Met129 and 
Arg131 (55). The guanidyl group of Arg131 may form a cation–π 
interaction to the biphenyl group of GSC839. Arg131 in human 
CD22, and Tyr66 in mouse CD22, the key residues for interaction 
with the biphenyl groups, correspond to Pro141 in mouse CD22 
and Pro62 in human CD22, respectively. Both of these prolines 
may not contribute to the affinity to the biphenyl group. Thus, 
human and mouse CD22 interact with the biphenyl groups of 
BPC-Neu5Ac and GSC839, respectively, with similar but distinct 
mechanisms, although GSC839 binds to human and mouse CD22 
with comparable affinity.
GSC718 was the first synthetic ligand for both human and 
mouse CD22 with nanomolar potency (6). Later, Prescher et al. 
developed a C2/C4/C9-modified sialoside that binds to human 
CD22 with higher affinity (2 nM) (8). However, selectivity to CD22 
of this sialoside has not yet been known. Rillahan et al. developed 
(200 nM) a C2/C5/C9-modified sialoside that selectively binds 
to human CD22 with the affinity comparable to or slightly less 
than that of GSC718 and GSC839 (9). Here, we demonstrated 
that CD22 is required for GSC839 to regulate antibody produc-
tion, and GSC839 does not induce production of inflammatory 
cytokines or recruit inflammatory cells. Thus, it is unlikely that 
GSC839 regulate other Siglecs than CD22. This is in agreement 
with our finding that GSC839 and GSC718 inhibit binding of 
recombinant CD22 but not other mouse Siglecs to cell surface 
ligands (Akatsu et  al., manuscript in preparation), indicating 
that these sialosides selectively bind to CD22. Thus, GSC718 and 
GSC839 show the highest affinity to CD22 as a selective CD22 
ligand so far developed. High-affinity CD22 ligands have been 
best developed as synthetic Siglec ligands. Synthetic ligands for 
other Siglecs still do not achieve IC50 of less than 100 nM (16).
In summary, synthetic sialosides that bind to mouse CD22 
with high-affinity by forming π–π interactions with CD22 
regulate B  cell activation in  vitro and augment antibody pro-
duction in mice. To our knowledge, this is the first example of 
monomeric high-affinity synthetic Siglec ligand that regulates 
immune responses in vivo. Our results suggest that development 
of the monomeric Siglec ligands that regulate other members of 
Siglecs may also be possible even if they do not possess druggable 
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pockets. Most of the Siglecs carry signaling function, and each 
member of the Siglec family is expressed in specific immune 
cell types. Thus, monomeric Siglec ligands that regulate distinct 
Siglecs may become unique compounds that contain immune 
regulatory activity although multimers of Siglec ligands and 
nanoparticles containing Siglec ligands have already been shown 
to possess therapeutic potentials by targeting various molecules 
to Siglecs.
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